Pharmacyte Biotech Inc (NASDAQ: PMCB) gave an update on its actions to remove the hold on treatment for inoperable, locally advanced pancreatic cancer from the U.S...
Pharmacyte Biotech Inc (NASDAQ: PMCB), in a statement, informed that the group had completed its 36-month Master Cell Bank stability study. Stability study paramount for group’s...
PharmaCyte Biotech Inc. (NASDAQ: PMCB) has announced additional results of a detailed analysis of the incorporation site of the cytochrome P450 2B1 Gene from augmented HEK293...
Pharmacyte Biotech Inc (NASDAQ: PMCB) has begun a study to determine if its treatment for inoperable, locally advanced pancreatic cancer can reduce the accumulation and production...
Pharmacyte Biotech Inc (NASDAQ: PMCB) announced the closure of underwritten public offering valued at $15 million. The company’s stock are currently trading on NASDAQ. H.C. Wainwright...
PharmaCyte Biotech Inc. (OTCMKTS: PMCB) has announced plans to effect a 1 for 1,500 reverse common stock split leaving it with around 1.6 million outstanding and...
